All-Trans-Retinoid Acid (ATRA) Induced Upregulation of Autophagy Related Proteins (LC3–1, II and Beclin 1) in Acute Promyelocytic Leukemia

2014 ◽  
Vol 10 (6) ◽  
pp. 315-321 ◽  
Author(s):  
Amany H. Mansour ◽  
Rokia Anwer ◽  
Ahmad Darwish ◽  
Abdulrahman Fahmi Alshaik ◽  
Mohamed Mabed
Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 936-945 ◽  
Author(s):  
Yirui Chen ◽  
Shouyun Li ◽  
Chunlin Zhou ◽  
Chengwen Li ◽  
Kun Ru ◽  
...  

Key Points A novel RARα fusion gene, TBLR1-RARα, was found in rare cases of APL with t(3;17) chromosomal translocation. TBLR1-RARα exhibited diminished transcriptional activity by recruiting more corepressors compared with RARα.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2012-2012 ◽  
Author(s):  
Bulent Ozpolat ◽  
Ugur Akar ◽  
Yasuko Kondo ◽  
Gabriel Lopez-Berestein

Abstract All-trans-retinoic acid (ATRA), a naturally occurring derivative of vitamin A (retinol), is a potent inducer of cellular differentiation, growth arrest, and apoptosis in various tumor cell lines. ATRA induces terminal differentiation of immature leukemic promyelocytes into normal mature granulocytes in vitro and in vivo, leading to a complete remission in majority of acute promyelocytic leukemia (APL) patients. Thus, this system provides an excellent in vitro model for studying the molecular events taking place during the terminal differentiation of myeloid cells. Apoptosis (type I) and autophagy (type II) are both highly regulated forms of programmed cell death and play crucial roles in such physiological processes as the development, homeostasis and elimination of unwanted cells. In contrast to apoptosis, autophagic cell death is caspase-independent and does not involve classic DNA laddering. Recent studies suggest that cancer cells in general tend to undergo less autophagy than their normal counterparts, supporting the contention that defective autophagic cell death plays a role in the process of carcinogenesis. The present study provides the first evidence that ATRA induces autophagy in acute promyelocytic leukemia cells. We demonstrated that treatment of APL (NB4) cells with ATRA resulted in a marked increase in formation of the acidic vesicular organelles demonstrated by acridine orange staining detected by flow cytometry. ATRA treatment caused about 12-fold increase in number of acridine orange positive cells compared to untreated group. Furthermore, ATRA induced marked upregulation of microtubule-associated protein light chain 3 (LC3-II), an important hallmark of autophagy, by western blot analysis. To determine the mechanim by which ATRA induces autophagy we examined expression of Beclin-1, an autophagy-inducing protein, and Bcl-2, an inhibitor of Beclin-1 as well as levels of mTOR, a suppressor of autophagy, upon ATRA treatment. ATRA inhibited Bcl-2, upregulated Beclin-1 expression and reduced induction of activation/phosphorylation of mTOR in NB4 cells. However, rapamycin, a specific inhibitor of mTOR failed to induce autophagy, suggesting that ATRA-mediated autophagy was independent of the mTOR pathway. We are currently testing whether inhibition of Beclin-1 can prevent ATRA-induced autophagy in APL cells. In conclusion, our results revealed that ATRA plays a role in regulation of autophagy by reducing Bcl-2 and inducing protein Beclin-1, which in turn induces autophagy, suggesting a novel action and mechanism of ATRA in regulation of autophagy in APL cells.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5595-5595 ◽  
Author(s):  
Daniel Morris

Abstract Acute Promyelocytic Leukemia (APL) is a hematologic emergency or urgency. It is a potential disaster that is also potentially curable. My research attempts to ascertain the readiness to care for patients who present with this (suspected) diagnosis and require urgent therapy. I polled a sample of approximately 140 (United States) hematologist-oncologists as to the availability of Tretinoin/all-trans retinoid acid (ATRA) on a stat basis at the hospitals at which they practice and 18 responded. In other words, is the medicine on the shelf and can be given when ordered. Available on the shelf and ready to give ATRA at all hospitals in which practiced: 2/18 Do not know: 3/18 Not available at all hospitals practiced: 13/18 Amazingly, one of the physicians stated that the family is given a prescription to get ATRA filled, and another responded that he had to "beg" to get the hospital to obtain it. I posted two questions on a social media site in the Emergency Medicine category; This social media web site states that the total physician membership is 343,000 (verified). The responses are as follows: Is ATRA on the shelf and available at the hospital they practice (17 responses to this question) 13/17 Do not know 2/17 On the shelf and available 2/17 Not on the shelf and would need to be ordered Is APL a possible question for board exam in Emergency Medicine? (16 responses to this question) 9/16 No 4/16 Not sure 3/16 Yes The price for ATRA according to www.uptodate.com is (Tretinoin Oral) 10 mg (100): $2988.16. Issues related to this topic include the cost, the supply (sold in quantities of 100), shelf life/expiration date, the agggregate cost to maintain it at every hospital based ER , and consideration that the patients are not all acutely ill and sometimes can wait a day before starting therapy. Even if this approach of not having ATRA in stock is not optimal, this approach is occurring. Whether or not Joint Commission or the more voluntary Commission on Cancer should require that ATRA be on the shelf at a hospital, or available within a certain amount of time may merit further discussion. Finding out how prepared we are to treat APL is not an easy undertaking and my effort seems to indicate that we probably do not have the wherewithal in many cases. Obtaining more data on the scope of the problem and perhaps devising a "Practice Guideline" by experts in the APL area dealing with the timeliness of availability of ATRA would seem to be in order. The lifesaving nature of the intervention would seem to justify the consideration of having hospitals maintaining a supply at all times. If the manufacturer would be willing to sell a supply of #30 (currently available in bottles of 100 per Facts and Comparison 2015 edition), this might be useful in implementing wider availability. Disclosures No relevant conflicts of interest to declare.


Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Xinxin Zhang ◽  
Li Liu ◽  
Yazhou Yao ◽  
Sha Gong ◽  
Mengchang Wang ◽  
...  

Abstract Background Acute promyelocytic leukemia (APL) is a highly curable disease when treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO). The combination of ATO and ATRA has become the standard therapeutic protocol for induction therapy in non-high-risk APL. An oral arsenic realgar-indigo naturalis formula (RIF) has also showed high efficacy and it has a more convenient route of administration than the standard intravenous regimen. Unlike in previous trials, the arsenical agent was used simultaneously with ATRA during post-remission therapy in this trial. Methods This study was designed as a multicenter, randomized controlled trial. The trial has a non-inferiority design with superiority being explored if non-inferiority is identified. All patients receive ATRA-ATO during the induction therapy. After achieving hematologic complete remission (HCR), patients were randomly assigned (1:1) to receive treatment with ATRA-RIF (experimental group) or ATRA-ATO (control group) as the consolidation therapy. During the consolidation therapy, the two groups receive ATRA plus RIF or intravenous ATO 2 weeks on and 2 to ~ 4 weeks off until molecular complete remission (MCR), then ATRA and oral RIF 2 weeks on and 2 to ~ 4 weeks off giving a total of six courses. Discussion This trial aims to compare the efficacy of ATRA-ATO versus ATRA-RIF in non-high-risk patients with APL, to demonstrate that oral RIF application reduces the total hospitalization days and medical costs. The simple schedule was studied in this trial. Trial registration ClinicalTrials.gov, NCT02899169. Registered on 14 September 2016.


2003 ◽  
Vol 20 (6) ◽  
pp. 337-343 ◽  
Author(s):  
Jen-Tsun Lin ◽  
Ming-Shiuan Wu ◽  
Wei-Shu Wang ◽  
Chueh-Chuan Yen ◽  
Tzeon-Jye Chiou ◽  
...  

Blood ◽  
2011 ◽  
Vol 117 (1) ◽  
pp. 242-245 ◽  
Author(s):  
Esperanza Such ◽  
José Cervera ◽  
Ana Valencia ◽  
Eva Barragán ◽  
Mariam Ibañez ◽  
...  

Abstract Chromosomal translocations in hematological malignancies often result in novel fusion chimeric genes. We report a case of acute myeloid leukemia with a clonal translocation t(11;12)(p15;q13) displaying morphologic and immunophenotypic features resembling the classical hypergranular subtype of acute promyelocytic leukemia. The gene fused to NUP98 (nucleoporin 98) was detected by comparative genomic hybridization array as the retinoid acid receptor gamma gene (RARG). The involvement of RARG in a chimeric fusion transcript has not been reported previously in human leukemia.


Sign in / Sign up

Export Citation Format

Share Document